| Drospirenone | Exeltis | ||
| 4 mg ; Tablets |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
|
Less Than 5
|
None | ||
| SLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy. | |||
|
Yes
| |||
| Slynd | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | **** ** ***** **, **** | *** ** ** | ********* | ********* | **** ** ***** **, **** | **** ** ** | **** ** ** (***** ******) | **** ** **** **, **** (***** ******) | **** ** ** (***** ******) | **** ** ** (***** ******) | **** ** *** **, **** (***** ******) | **** ** ** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** / *** | *** **, **** | ******* / ********* *** ** ** / ********* **** ** ** | ******** | ** *** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|